- Policy
- Would HIRA disclose DREC review result to drug industry?
- by Lee, Hye-Kyung Mar 18, 2020 06:34am
- Health Insurance Review and Assessment Service (HIRA) is contemplating on expanding the scope of disclosure regarding the Drug Reimbursement Evaluation Committee (DREC) deliberation. The contemplation would focus on whether or not to extend details of the deliberation to pharmaceutical companies after sufficiently reflecting their opinion
- Policy
- The NHIS recalculates ￦2 billion refund for pharmaceuticals
- by Lee, Hye-Kyung Mar 17, 2020 06:29am
- The NHIS has taken corrective action to settle the refund amount of the refund-type risk sharing agreement (RSA) through an internal audit. In the case of RSA drugs that have a 'double drug price' that differs from the drug price and the actual selling price, the NHIS notifies the pharmaceutical company of the payment of the medical instituti
- Company
- 2nd anti-CGRP migraine drug Ajovy seeks approval in Korea
- by Eo, Yun-Ho Mar 17, 2020 06:28am
- A second anti-calcitonin gene-related peptide (CGRP) treatment for migraine is preparing for the Korean market. According to pharmaceutical industry sources, Handok Teva has submitted approval application on CGRP targeted migraine treatment Ajovy (fremanezumab) aiming for the Ministry of Food and Drug Safety’s nod by late June. Ajov
- Company
- Amid COVID-19 industry conflicted with working from home
- by Kim, Jin-Gu Mar 17, 2020 06:28am
- The pharmaceutical industry is in a dilemma of working from home. Pharmaceutical companies that have given an order to work from home to a part or all of the office are conflicted whether to continue or to stop working from home. Depending on companies, some of them have already been working remotely for over a month. But they complain it i
- Company
- Lamisil distribution halted over 2 months inventory issue
- by Jung, Hye-Jin Mar 17, 2020 06:28am
- The distribution status of GlaxoSmithKline (GSK) Consumer Health’s anti-fungal treatment Lamisil has been unstable for a while. After the co-promotion deal with Dongwha Pharmaceutical has ended last year, GSK’s Lamisil has not been properly supplied for over two months. Although Zuellig Pharma Korea is negotiating with GSK on the Korean
- Company
- Pharmaceuticals, growth rate to be cut in half
- by Eo, Yun-Ho Mar 17, 2020 06:28am
- It was analyzed that the domestic pharmaceutical industry would be suffered hard from the aftermath of COVID-19. Drug market research firm IQVIA predicted that the growth of the Korean pharmaceutical market this year will be only 4.4%, half of the previous year due to the spread of COVID-19. This analysis compared changes found in major
- Company
- Supect by Il-Yang Pharm reduces COVID-19 by 70%
- by Jung, Hye-Jin Mar 17, 2020 06:27am
- Research has shown that Il-Yang Pharm's 'Supect' has the effect of reducing the COVID-19. Il-Yang Pharm announced on the 13th that as a result of experimenting with COVID-19 received from the KCDC, the virus in the group using Supect decreased by 70% within 48 hours. Supect (Radotinib) by Il-Yang Pharm is a leukemia treatment agent. This
- Company
- Herceptin market recovers ￦100 billion in three years
- by An, Kyung-Jin Mar 16, 2020 06:31am
- Domestically developed biosimilars enter the blockbuster anti-cancer drug 'Herceptin' market. The market share of the two products 'Herzuma' and 'Sampenet' exceeded 28%. The market size of Trastuzumab that Celltrion developed as 'Herjuma' shrank with the expansion of the biosimilar market has recovered to the level before drug price cuts.
- Academic lectures & student education are available online
- by 박상준 Mar 16, 2020 06:31am
- Due to the impact of COVID-19 spread, it shows signs of spread of “UNTACT” trend that seeks contactless non-face-to-face in the medical and pharmaceutical industries. As an alternative to canceling academic conferences and training courses, conference, hospitals, and medical schools are preparing or conducting online services, and the pharm
- Company
- Why Ezetimibe combination drug for dyslipidemia?
- by Eo, Yun-Ho Mar 16, 2020 06:30am
- For some diseases, combination drugs are vastly preferred than the other. Dipeptidyl peptidase-4 inhibitor plus metformin combination for patients with diabetes, and angiotensin II receptor blocker (ARB) plus calcium channel blocker (CCB) plus alpha combination for patients with hypertension haven taken over significant part of respectiv
